143 8 Clinical outcomes comparison of two different AOCs Respiratory therapies The OxyGenie cohort had significantly more time during which they received supplemental oxygen (table 2; 17.3 [6.0 – 31.1] days vs. 7.0 [1.1 – 26.1]; p = 0.045). High flow was not available in the AVEA ventilator, when excluding periods where infants where supported using high flow from the analysis there was a nonstatistically significant difference (8.5 [2.8 - 22.6) days OxyGenie group vs. 7.0 [1.1 – 26.1] CLiO2 group, p = 0.52). The mean inspired oxygen in the first week of life was similar in both groups (22.8 [21.8 – 25.0] % OxyGenie vs. 22.6 [21.4 – 24.8] %; p = 0.33), as was mean inspired oxygen during the entire stay (22.9 [21.8 – 25.3] % vs. 23.4 [21.6 – 27.0] %; p = 0.21). Infants in the OxyGenie cohort had fewer days of continuous positive airway pressure (CPAP; 8.4 [4.8 – 19.8] days vs. 16.7 [6.3 – 31.1] days; p < 0.001) and fewer days of invasive ventilation (0 [0 – 4.2] vs 2.1 [0 – 8.4]; p = 0.012) while the duration of nasal high flow was similar. There were no significant differences in number of infants who received inhaled nitric oxide, dexamethasone or surfactant. Table 2. Respiratory therapies OxyGenie CLiO2 p value* Invasive ventilation days, median [IQR] 0 [0 – 4.2] 2.1 [0 – 8.4] 0.012 CPAP days, median [IQR] 8.4 [4.8 – 19.8] 16.7 [6.3 – 31.1] <0.001 HFNC days, median [IQR] 10.0 [4.2 – 17.2] 8.2 [2.7 – 14.6] 0.20 Supplemental oxygen days, median [IQR] 17.3 [6.0 – 31.1] 7.0 [1.1 – 26.1] 0.045 excluding nasal high flow, median [IQR] 8.5 [2.8 – 22.6] 7.0 [1.1 – 26.1] 0.52 Mean inspired oxygen during first week, median [IQR] 22.8 [21.8 – 25.0] 22.6 [21.4 – 24.8] 0.33 entire admittance, median [IQR] 22.9 [21.8 – 25.3] 23.4 [21.6 – 27.0] 0.21 High frequency oscillation, n (%) 23 (19.0) 26 (21.5) 0.76 Inhaled nitric oxide, n (%) 13 (10.7) 15 (12.4) 0.85 Dexamethasone, n (%) 15 (12.4) 15 (12.4) 1.00 Surfactant, n (%) 67 (55.7) 69 (57.0) 0.89 via intubation, n (%) 28 (41.8) 38 (55.1) 0.32 via minimally invasive technique, n (%) 39 (58.2) 31 (44.9) CPAP, continuous positive airway pressure; HFNC, high flow nasal cannula; Average inspired oxygen while on respiratory support. *Statistical analysis with related-samples Wilcoxon signed rank, Bhapkar or related-samples McNemar test as appropriate.
RkJQdWJsaXNoZXIy MTk4NDMw